174 related articles for article (PubMed ID: 29676873)
1. [Bradykinin and cardiovascular protection. Role of perindopril, an inhibitor of angiotensin conversion enzyme].
Lancellotti P; Ancion A; D'Orio V; Gach O; Maréchal P; Krzesinski JM
Rev Med Liege; 2018 Apr; 73(4):197-205. PubMed ID: 29676873
[TBL] [Abstract][Full Text] [Related]
2. Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events.
Enseleit F; Hürlimann D; Lüscher TF
J Cardiovasc Pharmacol; 2001 Apr; 37 Suppl 1():S21-30. PubMed ID: 11392475
[TBL] [Abstract][Full Text] [Related]
3. Insight into the mode of action of ACE inhibition in coronary artery disease: the ultimate 'EUROPA' story.
Ferrari R; Fox K
Drugs; 2009; 69(3):265-77. PubMed ID: 19275271
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients.
Matsumoto T; Minai K; Horie H; Ohira N; Takashima H; Tarutani Y; Yasuda Y; Ozawa T; Matsuo S; Kinoshita M; Horie M
J Am Coll Cardiol; 2003 Apr; 41(8):1373-9. PubMed ID: 12706934
[TBL] [Abstract][Full Text] [Related]
5. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease.
Zhuo JL; Mendelsohn FA; Ohishi M
Hypertension; 2002 Feb; 39(2 Pt 2):634-8. PubMed ID: 11882622
[TBL] [Abstract][Full Text] [Related]
6. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.
Dinicolantonio JJ; Lavie CJ; O'Keefe JH
Postgrad Med; 2013 Jul; 125(4):154-68. PubMed ID: 23933903
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
Ferrari R
Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
[TBL] [Abstract][Full Text] [Related]
8. Significance of endothelial prostacyclin and nitric oxide in peripheral and pulmonary circulation.
Gryglewski RJ; Chłopicki S; Uracz W; Marcinkiewicz E
Med Sci Monit; 2001; 7(1):1-16. PubMed ID: 11208485
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity.
Taddei S; Bortolotto L
Am J Cardiovasc Drugs; 2016 Oct; 16(5):309-21. PubMed ID: 27260014
[TBL] [Abstract][Full Text] [Related]
10. The rationale and design of the PERindopril GENEtic association study (PERGENE): a pharmacogenetic analysis of angiotensin-converting enzyme inhibitor therapy in patients with stable coronary artery disease.
Brugts JJ; de Maat MP; Boersma E; Witteman JC; van Duijn C; Uitterlinden AG; Bertrand M; Remme W; Fox K; Ferrari R; Danser AH; Simoons ML;
Cardiovasc Drugs Ther; 2009 Apr; 23(2):171-81. PubMed ID: 19082699
[TBL] [Abstract][Full Text] [Related]
11. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT.
Ceconi C; Fox KM; Remme WJ; Simoons ML; Bertrand M; Parrinello G; Kluft C; Blann A; Cokkinos D; Ferrari R; ;
Cardiovasc Res; 2007 Jan; 73(1):237-46. PubMed ID: 17140552
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of neointima by angiotensin-converting enzyme inhibitor in porcine coronary artery balloon-injury model.
Matsumoto K; Morishita R; Moriguchi A; Tomita N; Aoki M; Sakonjo H; Matsumoto K; Nakamura T; Higaki J; Ogihara T
Hypertension; 2001 Feb; 37(2):270-4. PubMed ID: 11230284
[TBL] [Abstract][Full Text] [Related]
14. [Principles of choice of an angiotensin-converting enzyme inhibitor: specific features of perindopril].
Morozova TE; Gontarenko SV; Kuz'mina EP
Ter Arkh; 2014; 86(9):115-8. PubMed ID: 25518516
[TBL] [Abstract][Full Text] [Related]
15. Effects of angiotensin-converting enzyme inhibition and bradykinin peptides in rats with myocardial infarction.
Qu Z; Xu H; Tian Y
Int J Clin Exp Pathol; 2015; 8(3):3410-7. PubMed ID: 26045879
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention of CAD with ACE inhibitors: a struggle between life and death of the endothelium.
Ferrari R; Guardigli G; Ceconi C
Cardiovasc Drugs Ther; 2010 Aug; 24(4):331-9. PubMed ID: 20577898
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms involved in the angiotensin II-independent hypotensive action of ACE inhibitors.
Hecker M; Pörsti I; Busse R
Braz J Med Biol Res; 1994 Aug; 27(8):1917-21. PubMed ID: 7749381
[TBL] [Abstract][Full Text] [Related]
18. Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischaemic therapy?
Remme WJ
Drugs; 1997; 54 Suppl 5():59-70. PubMed ID: 9429846
[TBL] [Abstract][Full Text] [Related]
19. Tissue angiotensin-converting enzyme inhibitors: are they more effective than serum angiotensin-converting enzyme inhibitors?
Shah AD; Arora RR
Clin Cardiol; 2005 Dec; 28(12):551-5. PubMed ID: 16405197
[TBL] [Abstract][Full Text] [Related]
20. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
